The effects of Myo-Inositol (Inofolic supplement) on thyroid hormone function and symptoms of polycystic ovary syndrome

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150706023084N25

Enrollment

Registered

2025-07-26

Start date

2025-06-22

Completion date

Unknown

Last updated

2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovary syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: It includes 30 patients aged between 18-40 years who refer to hospitals of Islamic Azad University of Tehran and are diagnosed with polycystic ovary syndrome (PCOS)

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Women with polycystic ovary syndrome aged 18-40 years

Exclusion criteria

Exclusion criteria: Underlying conditions such as diabetes, high blood pressure, high cholesterol. Individuals with neurological or psychiatric disorders. individuals with high prolactin levels.

Design outcomes

Primary

Measure	Time frame
Menstrual irregularity. Timepoint: On days 0 and 60. Method of measurement: patient interview.;Follicle size (cyst). Timepoint: On days 0 and 60. Method of measurement: Ultrasound.;Number of follicles (cyst). Timepoint: On days 0 and 60. Method of measurement: Ultrasound.;Ovarian size. Timepoint: On days 0 and 60. Method of measurement: Ultrasound.;Thyroid hormones T3, T4, TSH. Timepoint: On days 0 and 60. Method of measurement: Blood test.	—

Measure

Time frame

Menstrual irregularity. Timepoint: On days 0 and 60. Method of measurement: patient interview.;Follicle size (cyst). Timepoint: On days 0 and 60. Method of measurement: Ultrasound.;Number of follicles (cyst). Timepoint: On days 0 and 60. Method of measurement: Ultrasound.;Ovarian size. Timepoint: On days 0 and 60. Method of measurement: Ultrasound.;Thyroid hormones T3, T4, TSH. Timepoint: On days 0 and 60. Method of measurement: Blood test.

—

Secondary

Measure	Time frame
Weight. Timepoint: On days 0 and 60. Method of measurement: patient interview.;Uteinizing hormone (LH). Timepoint: On days 0 and 60. Method of measurement: Blood test.;Follicle stimulating hormone (FSH). Timepoint: On days 0 and 60. Method of measurement: Blood test.;Estrogen. Timepoint: On days 0 and 60. Method of measurement: Blood test.;Testosterone. Timepoint: On days 0 and 60. Method of measurement: Blood test.;Free testosterone. Timepoint: On days 0 and 60. Method of measurement: Blood test.;Androstenedione. Timepoint: On days 0 and 60. Method of measurement: Blood test.	—

Measure

Time frame

Weight. Timepoint: On days 0 and 60. Method of measurement: patient interview.;Uteinizing hormone (LH). Timepoint: On days 0 and 60. Method of measurement: Blood test.;Follicle stimulating hormone (FSH). Timepoint: On days 0 and 60. Method of measurement: Blood test.;Estrogen. Timepoint: On days 0 and 60. Method of measurement: Blood test.;Testosterone. Timepoint: On days 0 and 60. Method of measurement: Blood test.;Free testosterone. Timepoint: On days 0 and 60. Method of measurement: Blood test.;Androstenedione. Timepoint: On days 0 and 60. Method of measurement: Blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Maryam Shiehmorteza

Islamic Azad University

shiehmorteza@iaups.ac.ir+98 21 2264 0056

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026